

Special Issue

New Advances in Cancer Immunotherapy

Message from the Guest Editor

The first use of immunotherapy against cancer emerged with the use of a mixture of bacterial toxins derived from the species of *Streptococcus pyogenes* and *Serratia marcescens* called Coley's toxin in sarcoma patients. Recent advances in therapy, such as PROTAC molecules, which target intracellular proteins involved in cancer development, mRNA vaccines, and enhanced CAR-T cell therapies, alongside continued development of checkpoint inhibitors and personalized vaccines, aim to improve efficacy, overcome resistance, and broaden the applicability of immunotherapy across various cancer types. This Special Issue addresses these therapies and includes a new form of tumor-infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, to improve treatment effectiveness.

Guest Editor

Dr. Vijay Kumar

Laboratory of Tumor Immunology and Immunotherapy, Department of Surgery Morehouse, School of Medicine Atlanta, Atlanta, GA 30310, USA

Deadline for manuscript submissions

31 May 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/251332

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).